A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy.

Oncotarget · 2014 · PMC4170649 · PMID 24979648

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

approaching significanceP=0.057so close (0.05 < p ≤ 0.1)

Unexpectedly, while a stronger inhibitory effect of bsFab could have been expected based on in vitro ADCC assays, HER2bsFab reduced JIMT-1 tumor growth, closely approaching significance (P=0.057).

also in 2,640 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.